BSE: SAKAR CMP: Rs 832.45 P/E: 60.77x ROCE: 12.67% 6M Ret: +103.43% Div Yld: Nil ATH: Rs 889.95
Key Performance Indicators
Sakar Healthcare trades at Rs 832.45 on BSE (SAKAR), with a market capitalisation of Rs 1852.19 crore. The price-to-earnings ratio is 60.77x. Return on capital employed stands at 12.67%. The six-month return is +103.43%. Quarterly net profit is Rs 11.02 crore (+91.32% year-on-year change). Quarterly sales stand at Rs 71.10 crore (+41.52% year-on-year). The all-time high is Rs 889.95, 6.9% above the current price.
Highlights
Sakar Healthcare has delivered a six-month return of 103.43%, with a market capitalisation of Rs 1852.19 crore at the current price of Rs 832.45. The all-time high of Rs 889.95 sits 6.9% above the current price, indicating the stock has corrected from its historical peak and offers headroom for appreciation toward that level. The company's ROCE of 12.67% — in the solid 12–15% range, indicating good capital efficiency — is a key distinguishing fundamental metric.
The P/E of 60.77x carries a moderate growth premium relative to the Indian market average, pricing in above-economy earnings growth expectations. The healthcare sector tailwinds — rising health insurance penetration, growing chronic disease burden, and government healthcare investment — provide structural support for sustained revenue and earnings growth.
Business Overview
Sakar Healthcare is a pharmaceutical company specialising in the manufacture of specialty pharmaceutical formulations — including soft gelatin capsules, liquid-filled hard capsules, and other advanced drug delivery formats. Specialty drug delivery technologies command premium pricing over standard tablet and capsule formulations, with applications in nutraceuticals, vitamins, pharmaceutical products, and over-the-counter wellness products. The company supplies to domestic pharmaceutical companies and export markets.
The quarterly profit of Rs 11.02 crore growing 91.32% on revenue of Rs 71.10 crore growing 41.52% year-on-year demonstrates accelerating growth momentum across both revenue and profitability dimensions. The ROCE of 12.67% is solid and improving. The P/E of 60.77 times reflects a growth premium applied to a specialty pharmaceutical business demonstrating rapid earnings expansion. The six-month return of 103.43% and the all-time high of Rs 889.95 — Rs 57.50 above the current price of Rs 832.45 — indicate meaningful appreciation potential toward the historical peak.
Financial Analysis
Sakar Healthcare's most recent quarterly financial results show revenue of Rs 71.10 crore (+41.52% year-on-year) and net profit of Rs 11.02 crore (91.32% year-on-year variation). Profit growth meaningfully exceeding revenue growth indicates improving profitability margins — a positive structural signal if it reflects genuine cost efficiency or product mix improvement rather than temporary factors.
The ROCE of 12.67% is the primary quality indicator for this business. At 12.67%, the business generates solid capital returns, indicating competitive positioning that allows it to earn above-average returns without extraordinary competitive advantages. Tracking ROCE improvement over time provides a leading indicator of business quality enhancement.
At Rs 1852.19 crore — a small-cap company — Sakar Healthcare may have limited institutional research coverage, making self-directed analysis of BSE exchange filings, quarterly results, and annual reports especially important for investors forming an investment view.
Investor Highlights
The investment case for Sakar Healthcare rests on the combination of a 12.67% ROCE — indicating a capital-efficient business with sustainable competitive advantages — and a demonstrated revenue and earnings growth trajectory that supports the current P/E of 60.77x. The combination of solid ROCE with consistent earnings growth creates a compounding engine where both business scale and per-share earnings grow simultaneously, supporting share price appreciation over a full investment cycle.
With the current price 6.9% below the all-time high of Rs 889.95, there is established headroom toward the historical peak. If fundamental performance continues to deliver quarterly profit growth and improving ROCE, the stock has a reference target for re-rating toward the all-time high level.
The absence of a dividend yield is consistent with a growth-phase reinvestment strategy — if the ROCE of 12.67% exceeds the shareholder's cost of equity, retaining earnings for reinvestment creates more value than distribution. Investors should assess whether management's capital allocation decisions (capex, acquisitions, working capital) are generating returns consistent with the current ROCE. Investors should access the company's latest annual report and quarterly results on the BSE/NSE portal for current financial data and management commentary on the growth outlook.
Frequently Asked Questions
Q: What does Sakar Healthcare do and why has it delivered a 103.43% six-month return?
A: Sakar Healthcare operates in India's healthcare sector. The 103.43% six-month return reflects a combination of sector-level tailwinds, improving quarterly financial performance — quarterly profit growing 91.32% and revenue growing 41.52% year-on-year — and market re-rating of the company's growth and quality profile. Specific business details and catalysts are documented in BSE/NSE exchange filings.
Q: What does the ROCE of 12.67% indicate about Sakar Healthcare's business quality?
A: Sakar Healthcare's ROCE of 12.67% measures pre-tax profit generated per rupee of total capital employed. At 12.67%, the business generates solid above-average returns on capital, indicating a competitive position that delivers good operating profitability relative to the asset base deployed. Tracking ROCE over multiple quarters provides a leading indicator of business quality improvement or deterioration.
Q: How does the P/E of 60.77x compare to fundamentals for Sakar Healthcare?
A: The P/E of 60.77x should be assessed in conjunction with the earnings growth rate and ROCE. At 60.77x, the stock carries a moderate premium relative to the market average of 20–25x, compensated in part by the ROCE of 12.67% and the quarterly earnings growth of 91.32%.
Q: What is Sakar Healthcare's all-time high and how far is the current price from it?
A: Sakar Healthcare's all-time high is Rs 889.95. The current price of Rs 832.45 is 6.9% below the all-time high, offering potential headroom for appreciation if fundamental performance supports continued market re-rating. The all-time high provides a reference ceiling that informs sentiment and potential price target discussion, though fundamental value — determined by earnings, ROCE, and growth — is the primary determinant of sustainable price levels.
Q: Where can investors access Sakar Healthcare's official financial data and disclosures?
A: Sakar Healthcare's quarterly results, annual reports, investor presentations, shareholding patterns, and all material corporate announcements are filed with BSE and are freely accessible through the exchange filing portals at nseindia.com and bseindia.com. SEBI listing regulations mandate timely disclosure of all financial results and material developments. These filings are the primary source of verified financial and operational data for investment analysis.